![]() |
|
![]() |
|
![]() |
|
![]() |
|
ITI has already executed three commercial partnerships – two with Astellas Pharma and one with Geron/Asterias. The Company believes these partnerships provide important validation of its scientific platform and partnering strategy. Initial license payments received exceed $300 million and pending milestone payments exceed $55 million. Additionally, ITI will receive double-digit royalties on allergy products, a market with multi-billion-dollar potential. ITI achieved this agreement while retaining the rights to the LAMP-Vax platform for other applications, including cancer immunotherapy. |
|
![]() |
|
![]() |
|